shutterstock-150798149

Illustration: RYGER / Shutterstock.com

6 June 2014Big Pharma

Pharma report calls for “wide debate” in Europe

Pharmaceutical professionals should have a “wide-ranging” debate on how IP can be tailored in the face of “major changes” to the industry, including the possibility of “prolonged exclusivity” for certain medicines, according to a report.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Lewis Roca promotes tech expert to managing partner

Panitch Schwarze brings in molecular biologist

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

ITC concludes row over biotech lab equipment between US and German rivals

UKIPO launches ‘revolutionary’ patent filing and AI tool

USPTO clarifies AI's role in patent eligibility